Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 4/20 | 0.38 |
| ▸ | PDGFRA | P16234 | 4/20 | 0.38 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.35 |
| ▸ | ESR1 | P03372 | 3/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | PRNP | P04156 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18571995 | 0.93 | PDGFRB (0.38) | PDGFRBPDGFRAEGFRDYRK1AESR1 | |
| SCHEMBL31475475 | 0.84 | PDGFRB (0.46) | PDGFRBPDGFRADYRK1AHTTHPGD | |
| SCHEMBL24096780 | 0.84 | PDGFRB (0.46) | PDGFRBPDGFRADYRK1AHTTHPGD | |
| SCHEMBL3216136 | 0.78 | PDGFRB (0.38) | PDGFRBPDGFRAEGFR | |
| SCHEMBL3214905 | 0.78 | NPSR1 (0.40) | PDGFRBPDGFRAEGFRDYRK1AHTT | |
| SCHEMBL3222941 | 0.78 | PLAU (0.39) | PDGFRBPDGFRAEGFRDYRK1AESR1 | |
| SCHEMBL18571804 | 0.74 | PLAU (0.39) | PDGFRBPDGFRAEGFRDYRK1AESR1 | |
| SCHEMBL21129928 | 0.74 | DYRK1A (0.35) | PDGFRBPDGFRADYRK1AHTTLMNA | |
| SCHEMBL23429990 | 0.74 | ALDH1A1 (0.36) | PDGFRBPDGFRADYRK1AHTTNPSR1 | |
| SCHEMBL29911356 | 0.74 | DYRK1A (0.35) | PDGFRBPDGFRADYRK1AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021074279-A1 | SPIRO-FUSED TRICYCLIC MAP4K1 INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2021-04-22 | — | — | WO | disclosed |
| CN-101522030-B | Fungicides | SYNGENTA PARTICIPATIONS AG | 2012-09-05 | — | — | CN | disclosed |
| US-20100056570-A1 | FUNGICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-03-04 | — | — | US | disclosed |
| WO-2010015680-A1 | FUNGICIDE OXYALKYLAMIDE DERIVATIVES | BAYER CROPSCIENCE SA (FR) | 2010-02-11 | — | — | WO | disclosed |
| CN-101522030-A | Fungicides | SYNGENTA PARTICIPATIONS AG (CH) | 2009-09-02 | — | — | CN | disclosed |
| EP-2068632-A1 | FUNGICIDES | Syngeta Participations AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008028624-A1 | FUNGICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2008-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056570-A1 | FUNGICIDES | CYP21A2, CYP51A1, CYP4X1 | PDGFRB 4516/4885PDGFRA 4427/4885EGFR 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.